Quote | Innate Pharma S.A. (NYSE:IPHA)
Last: | $ |
---|---|
Change Percent: | 1.60% |
Open: | $7.75 |
Close: | $7.60 |
High: | $7.75 |
Low: | $7.57 |
Volume: | 5,364 |
Last Trade Date Time: | 02/12/2020 04:44:19 pm |
News | Innate Pharma S.A. (NYSE:IPHA)
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
Message Board Posts | Innate Pharma S.A. (NYSE:IPHA)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading | lakoob2 | investorshub | 07/07/2023 2:27:48 PM |
Do we have a winner?Turn around time? | TheFinalCD | investorshub | 07/07/2023 5:16:31 AM |
$IPHA Good news recently, we should start to see this one move | tw0122 | investorshub | 07/05/2023 12:18:57 PM |
$IPHA short squeeze | crudeoil24 | investorshub | 07/05/2023 7:50:06 AM |
$IPHA where is the squeeze? | makinezmoney | investorshub | 07/03/2023 7:30:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Innate Pharma S.A. Company Name:
IPHA Stock Symbol:
NYSE Market:
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of Shareholders (“ AGM ”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Lumi...
Partner Sanofi advances SAR443579 / IPH6101, ANKET ® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first patient in the dose expansion part of the trial triggers a €4m milestone paym...
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models Prec...